Skip to content

Evaluation by Electrical Impedancemetry of the Variation in Lung Volumes Under Non-invasive Ventilation (NIV) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation by Electrical Impedancemetry of the Variation of Lung Volumes Under NIV in Patients With COPD

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05953298
Acronym
Eval 3V-BPCO
Enrollment
30
Registered
2023-07-20
Start date
2023-06-26
Completion date
2024-05-28
Last updated
2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Chronic obstructive pulmonary disease, non invasive ventilation, end-expiratory lung volume, electrical impedance tomography

Brief summary

The aim of this physiologic research is to assess lung volumes variations under NIV in stable COPD patients to understand the impact of high-intensity ventilation following the current recommendations. The main objective is to evaluate the variation of End-expiratory lung volume (EELV) reflecting the functional residual capacity (FRC), via the End-tidal lung impedance (EELI) obtained by electrical impedance tomography during a 20 minutes NIV session.

Detailed description

In patients with COPD, European recommendations recommend the use of NIV with a high pressure setting (1). These ventilatory modalities go against what is done in acute. Indeed, in this case, the pressures are much lower, because the risk of asynchronies and dynamic hyperinflation under NIV is then very important. The usual techniques for evaluating lung volume and dynamic hyperinflation do not allow this to be measured under NIV. Assessing lung volumes under NIV in stable COPD patients is therefore of major interest in understanding the impact of high-intensity ventilation. Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level.(2) Among these measures, the End-Expiratory Lung Impedance (EELI), strongly correlated to the End-Expiratory Lung Volume (EELV), is the reflection of the FRC and can be dynamically monitored in real time at the patient's bedside(3). However, it has never been used in stable COPD patients on NIV, and could be an interesting tool for analyzing the impact of NIV on lung volumes. The main objective is to evaluate the variation of EELV reflecting the functional residual capacity (FRC), via the End-tidal lung impedance (EELI) obtained by electrical impedance tomography, during a 20-minute session of NIV in patients with COPD at the stable state The secondary objectives will be: * To evaluate the variation of the EELV reflecting the FRC, via the EELI obtained by electrical impedance tomography, before, during and after a 20-minute session of NIV in stable-state COPD patients. * Evaluate the relationship between the variation of PtCO2, and that of EELV under NIV, reflection of the FRC, via the EELI obtained by electrical impedance tomography. * Identify responder and non-responder patient subgroups.

Interventions

DEVICEElectrical impedance tomography (EIT)

Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with COPD in stable condition fitted with long-term NIV followed at Bordeaux University Hospital; * Patient benefiting from social protection from the national health insurance fund; * Patient having read the patient information letter and given his non-objection to participate in the study.

Exclusion criteria

* Obesity with a BMI \> 35; * Respiratory exacerbation during treatment; * Patient with one or more contraindications to the implementation of EIT(7): * Pacemaker, defibrillator, electric active medical device; * Damaged skin condition, dressing on the observation area; * Risk related to fitting the belt (fracture, spinal lesions, etc.); * Uncontrollable movements; * Current electrotherapy; * Presence of a magnetic field (magnetic resonance imaging); * Other bioimpedance measurements in progress; * Pregnant woman ; * Tidal volume \< 1ml/kg; * Patient having read the patient information letter and refusing to participate in the study (Loi Jardé research category 3); * Patient under guardianship, curatorship, or deprived of freedom of administrative or judicial decision; * Patient included in other protocols that may interact with this study;

Design outcomes

Primary

MeasureTime frameDescription
End-Expiratory Lung Impedance (EELI) evolution during NIV sessionsDay 1End-Expiratory Lung impedance is related to the End-Expiratory Lung Volume reflecting the functional residual capacity (FRC). It is obtained by electrical impedance tomography. EELI values are presented in arbitrary values (v.a) and can vary greatly between individuals. Thus, as previously proposed by (4), the EELI values during the different measurement phases will be assessed and presented as a percentage change from their reference value. The main objective of this study aims to observe the evolution of the EELI under NIV in stable COPD patients, the reference EELI value will be that measured at T1 (NIV initiation+1 minute), compared to that measured at T2 (NIV+20minutes) under the ∆EELI%T2 abbreviation from the following calculation: ∆EELI%T2 = (EELIT1-EELIT2)/EELIT1\*100

Secondary

MeasureTime frameDescription
End-Expiratory Lung Impedance (EELI) evolution before, during and NIV sessionsDay 1A secondary objective of this research is to observe the evolution of the EELI before, during and after the NIV. In this context, the reference value will be the measurement of the EELI before the NIV, i.e. EELIT0. Thus the EELI values at T1 (NIV initiation+1 minute), T2 (NIV+20minutes) and T3 (5minutes after NIV) will be presented as a percentage change compared to T0 and will be respectively ∆EELI%T1, ∆EELI %T2 and ∆EELI%T3, respecting the following calculation: ∆EELI%Tx = (EELIT0-EELITx)/EELIT0\*100.
Transcutaneous capniaDay 1A secondary objective of this research is to observe the evolution of transcutaneous capnia (PtCO2) in mmHg via a capnograph before (T0), during (T1, T2) and after NIV (T3).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026